The real-world use of CAL/BDP PAD-cream was associated with improvement across multiple clinician- and patient-reported outcomes.

Abrocitinib shows sustained efficacy in treating moderate to severe AD across multiple clinical and patient-reported outcome measures.

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

Please provide your email address to receive an email when new articles are posted on . In business, the focus on consistent outcomes includes managing “inputs,” such as uniform materials and ...

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment. What is the potential impact of these novel treatments on disease progression, mortality, and ...

The American Academy of Sleep Medicine has developed and validated a patient-reported outcome tool for use in a clinical setting to monitor treatment response and longitudinal symptom progression in ...

Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...

Management of Malignant Pleural Effusion in 2024: A Definitive and Unified Global Approach Interestingly, though, the Danish multicenter randomized study 6 did not reproduce the survival benefit ...

Objective Unlike several other fields of healthcare, little is known about the size of ‘therapist effects’ on patient ...

Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 ...

Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...